RECENT ADVANCES IN CANCER DIAGNOSIS: INTEGRATION OF LIQUID BIOPSY, MOLECULAR BIOMARKERS, ARTIFICIAL INTELLIGENCE, AND ADVANCED IMAGING
DOI:
https://doi.org/10.55640/Keywords:
cancer diagnosis, liquid biopsy, molecular biomarkers, artificial intelligence, advanced imaging, precision oncologyAbstract
Early and accurate diagnosis of cancer is crucial for improving patient outcomes and survival rates. In recent years, rapid technological progress has transformed the field of cancer diagnostics, enabling earlier detection and more precise characterization of tumors. Novel diagnostic approaches such as liquid biopsy, molecular biomarkers, artificial intelligence (AI), and advanced imaging techniques are increasingly being integrated into clinical practice. Liquid biopsy allows non-invasive detection of tumor-derived components such as circulating tumor DNA and circulating tumor cells. Molecular biomarkers provide valuable insights into genetic and epigenetic alterations associated with malignancy. Artificial intelligence has demonstrated significant potential in enhancing radiological and histopathological interpretation, improving diagnostic accuracy and efficiency. Additionally, advanced imaging modalities including functional MRI and PET-CT offer improved tumor visualization and staging. The integration of these innovative technologies represents a paradigm shift toward precision oncology, enabling earlier detection, personalized treatment planning, and better monitoring of disease progression. This review summarizes recent advances in cancer diagnosis and highlights the potential of integrating emerging diagnostic technologies to improve cancer detection and management.
Downloads
References
1.Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide. CA Cancer J Clin. 2021;71(3):209-249.
2.Henry NL, Hayes DF. Cancer biomarkers. Mol Oncol. 2012;6(2):140-146.
3.Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, et al. Liquid biopsies come of age. Nat Rev Cancer. 2017;17(4):223-238.
4.Alix-Panabières C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA. Nat Rev Clin Oncol. 2016;13(6):325-337.
5.Bardelli A, Pantel K. Liquid biopsies and tumor evolution. Cancer Cell. 2017;31(2):172-173.
6.Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 2005;5(11):845-856.
7.Mardis ER. Next-generation sequencing platforms. Annu Rev Anal Chem. 2013;6:287-303.
8.Esteva A, Kuprel B, Novoa RA, Ko J, Swetter SM, Blau HM, et al. Dermatologist-level classification of skin cancer with deep neural networks. Nature. 2017;542:115-118.
9.McKinney SM, Sieniek M, Godbole V, Godwin J, Antropova N, Ashrafian H, et al. International evaluation of an AI system for breast cancer screening. Nature. 2020;577:89-94.
10.Jadvar H. FDG PET in oncology: basics and clinical applications. J Nucl Med. 2016;57(Suppl 1):144S-150S.
11.Lambin P, Leijenaar RTH, Deist TM, Peerlings J, de Jong EEC, Timmeren JV, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14(12):749-762.
12.Hood L, Friend SH. Predictive, personalized, preventive, participatory medicine (P4 medicine). Nat Rev Clin Oncol. 2011;8(3):184-187.
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

Germany
United States of America
Italy
United Kingdom
France
Canada
Uzbekistan
Japan
Republic of Korea
Australia
Spain
Switzerland
Sweden
Netherlands
China
India